BRCA1 and breast carcinoma: In contradiction with the above results, Byrski et al, reported a 61% pCR rate in 107 BRCA1 mutated, stage I to III breast cancer patient treated with four cycles of neoadjuvant cisplatin followed by surgery and adjuvant chemotherapy.